1-2 of 2
Emilia Flochova, MD PhD
Close
Sort by
Journal Articles

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Richard Greil, MD, Petra Obrtlikova, MD PhD, Lukas Smolej, MD PhD, Tomas Kozak, MDPhD, Michael Steurer, MD, Johannes Andel, MD, Josef Thaler, MD, Eva Mikuskova, MD, Liana Gercheva, MD, Thomas Nösslinger, MD, Miriam Ladicka, MD, Michael Girschikofsky, MD, MikulᚠHrubiško, MD PhD, Prof., Ulrich Jäger, MD, Michael A. Fridrik, MD, Martin Pecherstorfer, MD, Eva Kralikova, MD, Cristina Burcoveanu, MD, Stefcho Goranov, MD, Jana Jurkovikova, MD, Andreas L. Petzer, MD, Georgi G. Mihaylov, MD PhD, Julian Raynov, MD, Horst Oexle, MD, August Zabernigg, MD, Emilia Flochova, MD PhD, Stanislav Palasthy, MD, Thomas Melchardt, MD, Jiri Mayer, MD, Alexander Egle, MD
Journal: Blood
Blood (2014) 124 (21): 20.
https://doi.org/10.1182/blood.V124.21.20.20
Published: 2014
Journal Articles

Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile.

Anna Kreutzman, MSc, Peter Rohon, MD, Edgar Faber, MD, PhD, Karel Indrak, MD, PhD, Vesa Juvonen, PhD, Veli Kairisto, MD, PhD, Jaroslava Voglova, MD, Marjatta Sinisalo, MD, PhD, Emilia Flochova, MD, PhD, Petteri Arstila, MD, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1201.
https://doi.org/10.1182/blood.V116.21.1201.1201
Published: 2010